Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Characterization of disease progression in ovarian cancer by utilizing 'chemograms' of ovarian cancer stem cells.

Guddati AK, Shaheen S.

J Chemother. 2013 Jun;25(3):184-91. doi: 10.1179/1973947812Y.0000000058.

PMID:
23783145
2.

Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxin.

Casagrande F, Cocco E, Bellone S, Richter CE, Bellone M, Todeschini P, Siegel E, Varughese J, Arin-Silasi D, Azodi M, Rutherford TJ, Pecorelli S, Schwartz PE, Santin AD.

Cancer. 2011 Dec 15;117(24):5519-28. doi: 10.1002/cncr.26215. Epub 2011 Jun 20.

3.

Ovarian cancer stem cells: elusive targets for chemotherapy.

Guddati AK.

Med Oncol. 2012 Dec;29(5):3400-8. doi: 10.1007/s12032-012-0252-6. Epub 2012 May 26. Review.

PMID:
22638913
4.

FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.

Chiu WT, Huang YF, Tsai HY, Chen CC, Chang CH, Huang SC, Hsu KF, Chou CY.

Oncotarget. 2015 Feb 10;6(4):2349-65.

5.

A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.

Krivak TC, Lele S, Richard S, Secord AA, Leath CA 3rd, Brower SL, Tian C, Moore RG.

Am J Obstet Gynecol. 2014 Jul;211(1):68.e1-8. doi: 10.1016/j.ajog.2014.02.009. Epub 2014 Feb 12.

6.

Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma.

Chen X, Zhang J, Zhang Z, Li H, Cheng W, Liu J.

Hum Pathol. 2013 Nov;44(11):2373-84. doi: 10.1016/j.humpath.2013.05.001. Epub 2013 Jul 11. Review.

7.

Enrichment for chemoresistant ovarian cancer stem cells from human cell lines.

Cole JM, Joseph S, Sudhahar CG, Cowden Dahl KD.

J Vis Exp. 2014 Sep 10;(91):51891. doi: 10.3791/51891.

8.

Tumor recurrence and drug resistance properties of side population cells in high grade ovary cancer.

Zhang QH, Dou HT, Xu P, Zhuang SC, Liu PS.

Drug Res (Stuttg). 2015 Mar;65(3):153-7. doi: 10.1055/s-0034-1375609. Epub 2014 Dec 11.

PMID:
25504004
9.
10.

Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden.

Abubaker K, Latifi A, Luwor R, Nazaretian S, Zhu H, Quinn MA, Thompson EW, Findlay JK, Ahmed N.

Mol Cancer. 2013 Mar 27;12:24. doi: 10.1186/1476-4598-12-24.

11.

TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence.

Chefetz I, Alvero AB, Holmberg JC, Lebowitz N, Craveiro V, Yang-Hartwich Y, Yin G, Squillace L, Gurrea Soteras M, Aldo P, Mor G.

Cell Cycle. 2013 Feb 1;12(3):511-21. doi: 10.4161/cc.23406. Epub 2013 Jan 16.

12.

Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment.

Craveiro V, Yang-Hartwich Y, Holmberg JC, Joo WD, Sumi NJ, Pizzonia J, Griffin B, Gill SK, Silasi DA, Azodi M, Rutherford T, Alvero AB, Mor G.

Cancer Med. 2013 Dec;2(6):751-62. doi: 10.1002/cam4.115. Epub 2013 Aug 27. Erratum in: Cancer Med. 2013 Dec;2(6):987. Joo, Won Duk [added].

13.

Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.

Gaikwad SM, Thakur B, Sakpal A, Singh RK, Ray P.

Int J Biochem Cell Biol. 2015 Apr;61:90-102. doi: 10.1016/j.biocel.2015.02.001. Epub 2015 Feb 11.

PMID:
25681684
14.

ALDH1-bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome.

Wang YC, Yo YT, Lee HY, Liao YP, Chao TK, Su PH, Lai HC.

Am J Pathol. 2012 Mar;180(3):1159-69. doi: 10.1016/j.ajpath.2011.11.015. Epub 2012 Jan 2. Erratum in: Am J Pathol. 2012 Jul;181(1):374.

PMID:
22222226
15.

Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma.

Bonneau C, Rouzier R, Geyl C, Cortez A, Castela M, Lis R, Daraï E, Touboul C.

Gynecol Oncol. 2015 Jan;136(1):112-20. doi: 10.1016/j.ygyno.2014.10.024. Epub 2014 Nov 1.

PMID:
25449309
16.

ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer.

Lee M, Kim SW, Nam EJ, Cho H, Kim JH, Kim YT, Kim S.

Yonsei Med J. 2014 Nov;55(6):1664-71. doi: 10.3349/ymj.2014.55.6.1664.

17.

Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance.

Ahmed N, Abubaker K, Findlay J, Quinn M.

J Cell Biochem. 2013 Jan;114(1):21-34. doi: 10.1002/jcb.24317. Review.

PMID:
22887554
18.
19.

Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.

Furlong F, Fitzpatrick P, O'Toole S, Phelan S, McGrogan B, Maguire A, O'Grady A, Gallagher M, Prencipe M, McGoldrick A, McGettigan P, Brennan D, Sheils O, Martin C, W Kay E, O'Leary J, McCann A.

J Pathol. 2012 Apr;226(5):746-55. doi: 10.1002/path.3035. Epub 2012 Jan 17. Erratum in: J Pathol. 2014 Feb;232(3):e1.

20.

High frequency of putative ovarian cancer stem cells with CD44/CK19 coexpression is associated with decreased progression-free intervals in patients with recurrent epithelial ovarian cancer.

Liu M, Mor G, Cheng H, Xiang X, Hui P, Rutherford T, Yin G, Rimm DL, Holmberg J, Alvero A, Silasi DA.

Reprod Sci. 2013 May;20(5):605-15. doi: 10.1177/1933719112461183. Epub 2012 Nov 20.

Items per page

Supplemental Content

Write to the Help Desk